在去势抵抗性前列腺癌中具有潜在活性的雄激素受体拮抗剂的研发。
Development of androgen receptor antagonists with promising activity in castration-resistant prostate cancer.
作者信息
Shen Howard C, Balk Steven P
机构信息
Department of Medicine, Hematology-Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
出版信息
Cancer Cell. 2009 Jun 2;15(6):461-3. doi: 10.1016/j.ccr.2009.05.005.
PMID:19477425
Abstract
Androgen receptor (AR) continues to play a central role in prostate cancers that relapse after androgen deprivation therapy, but these tumors are refractory to available AR antagonists. In a recent issue of Science, Tran et al. describe an antagonist that prevents AR recruitment to chromatin and shows efficacy in relapsed prostate cancer.
摘要
雄激素受体（AR）在雄激素剥夺治疗后复发的前列腺癌中仍起着核心作用，但这些肿瘤对现有的AR拮抗剂具有抗性。在最近一期的《科学》杂志上，Tran等人描述了一种可阻止AR与染色质结合的拮抗剂，并在复发性前列腺癌中显示出疗效。
Zotero 插件